Published in TB and Outbreaks Week, September 15th, 1997
As part of the same research program, Cel-Sci Corp. has been developing the HGP-30 HIV vaccine. This vaccine has been tested in over 60 individuals and is expected to go into Phase II studies soon.
Cel-Sci Corp. has been developing Multikine for the treatment of cancers and other immunodeficiency diseases. In addition, it is developing the HGP-30 HIV vaccine/treatment and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week